Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845542 | 0.86 | CRBN (0.51) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL20128632 | 0.86 | CRBN (0.51) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL20128631 | 0.86 | CRBN (0.51) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL26188392 | 0.84 | HTR2A (0.37) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL25876256 | 0.82 | CRBN (0.43) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL26375162 | 0.76 | KMT2A (0.42) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL29312172 | 0.75 | CRBN (0.50) | HTR2AHTR2CHTR2BCRBNDDB1 | |
| SCHEMBL29312174 | 0.75 | CRBN (0.50) | HTR2AHTR2CHTR2BCRBNDDB1 | |
| SCHEMBL24369042 | 0.74 | KMT2A (0.53) | KMT2AHTR2AHTR2CHTR2BCRBN | |
| SCHEMBL20128648 | 0.72 | KMT2A (0.47) | KMT2AHTR2AHTR2CHTR2BCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160312292-A1 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | CELGENE CORP (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312292-A1 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | BCL6, BCL3, BCL6B | KMT2A 680/4885HTR2A 1120/4885HTR2C 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.